Biotech Values

[Biowatch]

>MNTA has designed a heparin variant called M118 from the ground up that works on both FXa and FIIa, is reversible, and doesn’t have the monitoring and reliability problems of ordinary heparin. If it works as advertised, it will be a monumental blockbuster, but it’s still very early in development.<

Naive question: Is MNTA working on a single isoform of heparin, or a carefully designed and reproducible set of the multiple forms found in vivo? The wide range of heparin forms found in vivo might imply variability is useful.

How do you decide what is best?